Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease

Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Amer J Respir Crit Care Med 1997; 155(4): 1283–9 Rennard SI, Anderson W, ZuWallack R, et al. Use of long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087–92 Burge PS, Calverley PMA, Jones PW, et al., on behalf of the ISOLDE Study Investigators. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May 13; 320: 1297–303 Calverley PMA, Pauwels RA, Vestbo J, et al., on behalf of the TRISTAN Study Group. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD [abstract]. Am J Respir Crit Care Med 2002; 165(8 Suppl.): A226 Pauwels RA, Buist AS, Calverley PMA, et al., on behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD): Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–76